N-(5-cyano-1,3-dimethylpyrazol-4-yl)formamide | 89239-21-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(5-cyano-1,3-dimethylpyrazol-4-yl)formamide
• 英文别名: N-(5-Cyano-1,3-dimethyl-1H-pyrazol-4-yl)formamide
• CAS: 89239-21-4
• 化学式: C₇H₈N₄O
• 分子量: 164.167
• InChiKey: ZOEJGZDMVLLUJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  70.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(5-cyano-1,3-dimethylpyrazol-4-yl)formamide 在 sodium hydroxide 、 五氯化磷 、 双氧水 、 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 N-(1,3-dimethyl-1H-pyrazolo<4,3-d>pyrimidin-7-yl)-2-aminoethanol
  参考文献：
  名称：

  Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines

  摘要：

  The synthesis of a series of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines is reported along with the effects of these compounds in preclinical tests for antipsychotic activity. Certain of these compounds displayed antipsychotic-like effects in conditioned avoidance tests, but unlike currently used antipsychotic drugs, they did not have affinity for brain dopamine receptors. These compounds also did not cause dystonias predictive of extrapyramidal side effects in monkeys at doses that produced behavioral effects. On the basis of this unique biological profile, a member of this series 7,8-dihydro-8-ethyl-1,3,5-trimethyl-1H-imidao[1,2-c]pyrazol[3,4-e] pyrimidine (19, CI-943), has been selected for clinical evaluation as an antipsychotic agent.

  DOI：

  10.1021/jm00397a032
• 作为产物：
  描述：

  4-amino-5-cyano-1,3-dimethyl pyrazole 、 甲乙酐 在 乙醚 作用下， 反应 16.0h， 以to give 14.5 g (74%) of N-(5-cyano-1,3-dimethylpyrazol-4-yl) formamide, mp 135° C.的产率得到N-(5-cyano-1,3-dimethylpyrazol-4-yl)formamide
  参考文献：
  名称：

  Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines

  摘要：

  描述了烷基咪唑[1,2-c]吡唑并[3,4-e]嘧啶以及药学上可接受的盐。这些化合物是抗精神病药物。还描述了它们的制备方法、含有它们的制药组合物以及使用这些组合物的方法。

  公开号：

  US04469868A1

文献信息

• Imidazo(1,2-c)pyrazolo(3,4-e)pyrimidines and their production
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0095289A2

  公开（公告）日：1983-11-30

  Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines and pharmaceutically acceptable salts are described. These compounds are useful as antipsychotic agents; processes for their preparation, and pharmaceutical compositions which contain them are also described.

  本文描述了烷基咪唑[1,2-c]吡唑并[3,4-e]嘧啶和药学上可接受的盐。这些化合物可用作抗精神病药物；还描述了它们的制备过程和含有它们的制药组合物。
• US4469868A
  申请人：——

  公开号：US4469868A

  公开（公告）日：1984-09-04
• Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
  作者：Horace A. DeWald、Nicholas W. Beeson、Fred M. Hershenson、Lawrence D. Wise、David A. Downs、Thomas G. Heffner、Linda L. Coughenour、Thomas A. Pugsley

  DOI：10.1021/jm00397a032

  日期：1988.2

  The synthesis of a series of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines is reported along with the effects of these compounds in preclinical tests for antipsychotic activity. Certain of these compounds displayed antipsychotic-like effects in conditioned avoidance tests, but unlike currently used antipsychotic drugs, they did not have affinity for brain dopamine receptors. These compounds also did not cause dystonias predictive of extrapyramidal side effects in monkeys at doses that produced behavioral effects. On the basis of this unique biological profile, a member of this series 7,8-dihydro-8-ethyl-1,3,5-trimethyl-1H-imidao[1,2-c]pyrazol[3,4-e] pyrimidine (19, CI-943), has been selected for clinical evaluation as an antipsychotic agent.
• Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
  申请人：Warner-Lambert Company

  公开号：US04469868A1

  公开（公告）日：1984-09-04

  Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines and pharmaceutically acceptable salts are described. These compounds are antipsychotic agents. Methods for their preparation, pharmaceutical compositions which contain them and methods for using said compositions are also described.

  描述了烷基咪唑[1,2-c]吡唑并[3,4-e]嘧啶以及药学上可接受的盐。这些化合物是抗精神病药物。还描述了它们的制备方法、含有它们的制药组合物以及使用这些组合物的方法。